Barclays Maintains Overweight on Merck & Co, Lowers Price Target to $142
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Merck & Co (NYSE:MRK) but lowers the price target from $145 to $142.
July 31, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Merck & Co (NYSE:MRK) but lowers the price target from $145 to $142.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100